ELISA Kit for Activin A (ACVA) Homo sapiens (Human) Competition ELISA

ACV-A; Activin Beta A Beta A Homodimer

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • ELISA Kit for Activin A (ACVA) Packages (Simulation)
  • ELISA Kit for Activin A (ACVA) Packages (Simulation)
  • ELISA Kit for Activin A (ACVA) Results demonstration
  • CEA001Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Activin A (ACVA) and the recovery rates were calculated by comparing the measured value to the expected amount of Activin A (ACVA) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 88-102 92
EDTA plasma(n=5) 78-99 88
heparin plasma(n=5) 86-93 89

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Activin A (ACVA) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Activin A (ACVA) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Activin A (ACVA) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 88-99% 80-103% 95-103% 97-104%
EDTA plasma(n=5) 83-96% 85-92% 84-101% 98-105%
heparin plasma(n=5) 97-105% 89-98% 90-97% 96-103%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1 Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Reagent Diluent 1×300µL Stop Solution 1×6mL
TMB Substrate 1×9mL Instruction manual 1
Wash Buffer (30 × concentrate) 1×20mL

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well.
    And then add 50µL prepared Detection Reagent A immediately.
    Shake and mix. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
5. Aspirate and wash 5 times;
6. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
7. Add 50µL Stop Solution. Read at 450 nm immediately.

ELISA Kit for Activin A (ACVA)

Test principle

This assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Activin A (ACVA) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Activin A (ACVA) and unlabeled Activin A (ACVA) (Standards or samples) with the pre-coated antibody specific to Activin A (ACVA). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Activin A (ACVA) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Activin A (ACVA) in the sample.

Citations

  • Secretory Products From Epicardial Adipose Tissue of Patients With Type 2 Diabetes Mellitus Induce Cardiomyocyte DysfunctionAhajournals: Source
  • Article: Hksobf_2015_V46N2_167
  • Methods for Diagnosis and Treatment of Concussion or Brain Injury2016:0103140
  • Activins and their related proteins in colon carcinogenesis: insights from early and advanced azoxymethane rat models of colon cancer.pubmed:27835986
  • Magnolol Attenuates Concanavalin A-induced Hepatic Fibrosis, Inhibits CD4+ T Helper 17 (Th17) Cell Differentiation and Suppresses Hepatic Stellate Cell Activation: Blockade of Smad3/Smad4 Signalling.pubmed:28032440
  • Magnolol Attenuates Concanavalin A-induced Hepatic Fibrosis, Inhibits CD4 + T Helper 17(Th17) Cell Differentiation and Suppresses Hepatic Stellate Cell Activation: Blockade of Smad3/Smad4 Signallingdoi:10.1111
  • MicroRNA-27b Modulates Inflammatory Response and Apoptosis during Mycobacterium tuberculosis InfectionPubmed:29661829
  • Expression of platelet-derived growth factor B is upregulated in patients with thoracic aortic dissectionPubmed:29685513
  • Toxic effects of arsenic trioxide on protoscoleces through ROS production, and Ca-ER stress-dependent apoptosis10.1093:abbs
  • The effect of raw and fermented rapeseed cake on the metabolic parameters, immune status, and intestinal morphology of turkeysPubmed:29917099
  • Characterization of Phospholipids from Pacific Saury () Viscera and Their Neuroprotective Activity10.1016:j.fbio.2018.06.002
  • Single Wall Carbon Nanotube and Magnetic Bead Based Electrochemical Immunosensor for Sensitive Detection of Salivary Secretory Immunoglobulin A10.2174:2211556006666170525161225
  • FRIDAY, NOVEMBER 3, 2017 11.30-12.0 BALLROOM AB:
  • SEROPREVALENCE OF ANTI-MANNOSE BINDING LECTIN AUTOANTIBODIES IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SANA'A CITY-YEMEN10.22270:ujpr.v3i2.138
  • Involvement of RBP4 in diabetic atherosclerosis and the role of vitamin D intervention:
  • Gingival crevicular fluid levels of human beta-defensin-1 in type 2 diabetes mellitus and periodontitisPubmed:29713888
  • Myocardial fibrosis in hypertrophic cardiomyopathy:
  • TELLING TRANSVERSAL COMPETENCES… TO BE PROFESSIONALLY PROMOTED:
  • Protein biomarker panels for detecting colorectal cancer and advanced adenoma:
  • Endothelotropic activity of 4-hydroxy-3, 5-di-tret-butylcinnamic acid in the conditions of experimental cerebral ischemia:
  • Silencing of the CSNK2β gene by siRNA inhibits invasiveness and growth of MDA-MB-231 cells10.1101:311092
  • Flow Cytometry-Defined CD49d Expression in Circulating T-Lymphocytes Is a Biomarker for Disease Progression in Duchenne Muscular DystrophyPubmed:29067667
  • SS
  • PP
  • DD
  • hh
  • OO
  • MM
  • EE
  • II
  • BB
  • TT
  • NN
  • LL
  • JJ
  • Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumorsPubmed: 30952517
  • The performances of serum activins and follistatin in the diagnosis of ectopic pregnancy: A prospective case-control studyPubmed: 31647905
  • The Association between the Activin A Serum Level and Carotid Intima-Media Thickness in Chronic Kidney Disease Patients
  • Profiling Activins and Follistatin in Colorectal Cancer According to Clinical Stage, Tumour Sidedness and Smad4 Status34867090

Recommend products